9-Oct-2026
PMV Pharmaceuticals Appoints Matt Eckler, Ph.D., to Board of Directors
Globe Newswire (Mon, 5-Oct 8:00 AM ET)
PMV Pharmaceuticals Appoints Philip Herman as Chief Commercial Officer
Globe Newswire (Tue, 8-Sep 8:00 AM ET)
PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities
Globe Newswire (Mon, 31-Aug 11:03 PM ET)
PMV Pharma Announces Proposed Public Offering of Securities
Globe Newswire (Mon, 31-Aug 4:02 PM ET)
Globe Newswire (Mon, 31-Aug 4:01 PM ET)
PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights
Globe Newswire (Fri, 14-Aug 8:00 AM ET)
Market Chameleon (Fri, 27-Feb 5:37 AM ET)
Market Chameleon (Thu, 26-Feb 6:26 AM ET)
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.
PMV Pharmaceuticals trades on the NASDAQ stock market under the symbol PMVP.
As of October 9, 2026, PMVP stock price climbed to $1.52 with 889,529 million shares trading.
PMVP has a beta of 0.18, meaning it tends to be less sensitive to market movements. PMVP has a correlation of 0.00 to the broad based SPY ETF.
PMVP has a market cap of $81.26 million. This is considered a Micro Cap stock.
In the last 3 years, PMVP traded as high as $6.55 and as low as $.81.
The top ETF exchange traded funds that PMVP belongs to (by Net Assets): VTI, VXF, IWC, BUSM, AVTM.
PMVP has underperformed the market in the last year with a return of +9.4%, while SPY returned +17.1%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in PMVP shares. However, PMVP has outperformed the market in the last 3 month and 2 week periods, returning +22.6% and +14.3%, while SPY returned +3.8% and +0.9%, respectively. This indicates PMVP has been having a stronger performance recently.
PMVP support price is $1.40 and resistance is $1.58 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PMVP shares will trade within this expected range on the day.